ArticleJournal of ovarian research2023

The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.

Youwen Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.